Cost-effectiveness analysis of antiviral treatment for pregnant women with high viral load to prevent hepatitis B virus vertical transmission.
Vertical transmission of hepatitis B virus (HBV) is higher in infants born to pregnant women with higher HBV DNA viral load despite infants completing both active and passive vaccination. Although antiviral treatment is recommended to pregnant women during the antenatal period to reduce the vertical transmission rate, most of them decline. A decision tree was made to evaluate the costs and benefits involved when pregnant women agree to take antiviral treatment during the antenatal period as well as when they decline. The cost-effectiveness price was arrived at by multiplying the reduced vertical transmission rate with expenses of future medical care associated with vertical transmission. Given the observed medication price and transmission rate in Singapore, from an individual's perspective, it was not cost-effective to receive antenatal antiviral treatment. However, from the health system's perspective, the current price of antiviral treatment was already far below the cost-effectiveness level, even without Ministry of Health subsidies. Additionally, pregnant women's awareness and perception also made an impact on treatment decisions. By analysing the decision-making process, our result explained the current low uptake rates of antenatal antiviral treatment for HBV among pregnant women. We also concluded that from the health system's perspective, it was worth providing subsidy for perinatal antiviral treatment to prevent huge expenses generated in the future by chronic HBV complications.